213 related articles for article (PubMed ID: 32273395)
1. Reslizumab as add-on therapy in patients with refractory asthma.
Virchow JC; McDonald M; Garin M; Korn S
BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32273395
[No Abstract] [Full Text] [Related]
2. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
3. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
Albers FC; Price RG; Smith SG; Yancey SW
J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
[No Abstract] [Full Text] [Related]
4. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
5. Reslizumab in Eosinophilic Asthma: A Review.
Deeks ED; Brusselle G
Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
[TBL] [Abstract][Full Text] [Related]
7. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
8. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab use: Post-approval academic practice experience.
Benjamin MR; Bochner BS; Peters AT
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
[No Abstract] [Full Text] [Related]
10. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.
d'Ancona G; Kavanagh JE; Dhariwal J; Hearn AP; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Jackson DJ; Kent BD
Allergy; 2021 Jul; 76(7):2238-2241. PubMed ID: 33432682
[No Abstract] [Full Text] [Related]
11. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
12. Mepolizumab (Nucala) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
[No Abstract] [Full Text] [Related]
13. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
14. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
16. Biologic Therapy in a Patient with Asthma and Nasal Polyps.
Caminati M; Senna G
J Allergy Clin Immunol Pract; 2019; 7(5):1700-1701. PubMed ID: 31076065
[No Abstract] [Full Text] [Related]
17. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
[TBL] [Abstract][Full Text] [Related]
18. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
Kurosawa M; Sutoh E
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
[No Abstract] [Full Text] [Related]
19. Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
Bateman ED; Djukanović R; Castro M; Canvin J; Germinaro M; Noble R; Garin M; Buhl R
Am J Respir Crit Care Med; 2019 Feb; 199(4):489-495. PubMed ID: 30346831
[TBL] [Abstract][Full Text] [Related]
20. Mometasone/Formoterol (dulera) for asthma.
Med Lett Drugs Ther; 2010 Oct; 52(1349):83-4. PubMed ID: 21045758
[No Abstract] [Full Text] [Related]
[Next] [New Search]